Health Care · Pharmaceutical Preparations

ZYME Zymeworks Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 193765365 filings
Russell 2000

ZYME at a glance

Zymeworks Inc. (ZYME, SEC CIK 1937653) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Zymeworks Inc. (ZYME) reported revenue of $106.0 million (up 38.9% from FY2024) and a net loss of $81.1 million. Diluted EPS was -$1.08.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Zymeworks Inc. (ZYME) shares worth $420.8 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Platshon Scott on November 18, 2026 of 15,292 shares at $24.95 per share.
  • In the last 90 days, ZYME insiders reported 0 open-market purchases ($0) and 5 open-market sales ($1.8M) on Form 4, a net sale of $1.8M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$106.0M
+38.9% vs prior year
Insiders · 90 days
0 buys · 5 sells
Net −$1.8M
13F holders
27 funds
$420.8M · +0 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 7.01 · Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: biotechnology company developing multifunctional antibody-based therapeutics for cancer, inflammation, and autoimmune diseases
  • New emphasis: commercial launch and milestone revenue focus on Ziihera (zanidatamab-hrii), approved in biliary tract cancer and pending broader regulatory approvals
  • Strategic shift: royalty financing via $250M sale of 30% future Ziihera royalties to Royalty Pharma supporting capital and reducing risk
  • Key metric: milestone payments received $69.9M in 2025 from partners; potential up to $440M near-term Ziihera milestones from Jazz and BeOne
  • Noteworthy fact: use of a special purpose entity to securitize royalties linked to Jazz Collaboration Agreement with a $250M loan maturing in 2042

Risk Factors

  • Regulatory risk: BIOSECURE Act may restrict U.S. government contracts to companies using equipment/services from certain Chinese biotech firms, affecting partnerships and operations
  • Geopolitical risk: Early-stage clinical supplies sourced from China exposed to ongoing U.S.-China trade tensions and tariffs, risking supply chain disruptions
  • Operational risk: Dependence on third-party manufacturers and collaborators; manufacturing difficulties could delay product supply for clinical trials or commercialization
  • Competitive risk: Intense competition from better-resourced companies for asset acquisitions may force paying higher prices, reducing potential returns
  • Financial risk: Historical losses with only zanidatamab generating royalties; no other product approvals or revenues as of December 31, 2025

Management Discussion & Analysis

  • Revenue $106.0M in 2025, up $29.7M (39%) YoY driven by milestone payments from J&J, BeOne, GSK, Daiichi Sankyo, and BMS
  • Operating expenses: R&D $137.0M (up 2% YoY), G&A $61.5M (flat YoY); R&D increased due to early-stage programs, zanidatamab R&D down 115% to $(1.8)M
  • Best segment: Collaboration revenue milestone growth from multiple partners; worst segment: Zanidatamab R&D costs down $13.7M due to program transition to Jazz
  • Cash $270.6M as of Dec 31, 2025; share repurchase $92.5M ($30M completed in 2025, $62.5M through Feb 2026); new $250M loan with Royalty Pharma in March 2026
  • Outlook: 2026 focus on Phase 1 trials for ZW191 and ZW251; IND filings for multispecific antibodies on track; Jazz plans zanidatamab sBLA Q1 2026 and potential commercial launch H2 2026

AI summary of the ZYME 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $256.5M vs $27.6M, up $228.9M YoY, driven by $250.0M Jazz milestone
  • Royalty and other revenue $4.9M vs $2.4M, while YUPELRI collaboration revenue contributed $1.5M
  • R&D expense $36.1M vs $35.6M, SG&A $42.7M vs $14.1M, with no quarterly margin figures disclosed
  • Cash $100.5M at September 30, operating cash flow nine-month outflow $101.7M vs $22.7M
  • $14.0M Q3 share repurchases, $532.0M Theravance acquisition payment, $250.0M Jazz milestone received October 2026
  • Outlook: cash plus Jazz milestone funding expected for at least twelve months, 2026 profitability anticipated but inconsistent quarterly profitability expected

Risk Factors

  • New trade-compliance risk: BIOSECURE Act and DOJ Data Security Program could restrict Chinese suppliers and sensitive-data transfers
  • Most material update: 10% global import surcharge and proposed 100% pharmaceutical tariff, threatening China-sourced clinical supplies
  • Regulatory risk: FDA accelerated BTC approval for Ziihera remains contingent on confirmatory-trial benefit
  • Operational risk: single YUPELRI API supplier, drug-product supplier and warehouse create concentrated supply exposure
  • Financial risk: $100 million TRELEGY ELLIPTA milestone anticipated in Q1 2027, subject to conditions and unavailable development information

AI summary of the ZYME 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Second 2026 Share Repurchase Program announced, signaling continued capital return to shareholders
  • Potential reduction in shares outstanding, supporting per-share metrics if repurchases are executed

Item 8.01: Other Events

  • New $200.0 million share repurchase authorization through 2028
  • Initial 2026 program completed after $125.0 million authorization

Item EX-99.1: Item EX-99.1

  • $200 million repurchase authorization through 2028, with approximately $140 million currently expected to be deployed
  • Program launch before year-end 2026, following completion of the initial $125 million authorization
Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for the three months ended September 30, 2026
  • Full financial details and management commentary contained in Exhibit 99.1, the attached press release

Item 7.01: Regulation FD Disclosure

  • Zymeworks identifies SEC filings, press releases, investor websites, conferences and social media as potential sources of material information
  • Investors should monitor these channels for updates on product candidates, corporate developments and other market-sensitive disclosures

Item EX-99.1: Item EX-99.1

  • 3Q revenue $256.5M vs $27.6M, driven by $250.0M Ziihera approval milestone from Jazz
  • 2026 guidance raised: revenue $337M-$351M and Adjusted EBITDA $176M-$190M
Filed Nov 9, 2026Full analysis →

Item EX-99.3: Item EX-99.3

  • Pro forma combined revenue $321.2M and net income $11.8M for nine months ended September 30, 2026
  • Full-year 2025 pro forma revenue $213.4M, but net loss $43.7M after merger and financing adjustments

AI summaries of ZYME 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ZYME

Don't miss the next ZYME filing

  • Alerts as it files. A push when ZYME files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ZYME, by share count.
  • Ask anything. An AI agent that reads every ZYME filing and answers with sources.

ZYME alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Platshon ScottSellNov 18, 2026$24.95
Platshon ScottMNov 18, 2026-
Platshon ScottMNov 18, 2026-
Moore Paul AndrewMNov 13, 2026-
Moore Paul AndrewSellNov 13, 2026$26.09
Moore Paul AndrewSellNov 13, 2026$26.04
Moore Paul AndrewMNov 13, 2026$5.82
Moore Paul AndrewSellNov 13, 2026$26.14

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$76.3M$106.0M
Operating Income--$137.1M-$92.5M
Net Income-$118.7M-$122.7M-$81.1M
Op. Margin--179.7%-87.3%
Net Margin--160.8%-76.6%
Balance Sheet
Total Assets$580.9M$463.1M$346.5M
Equity-$338.8M$268.5M
ROE--36.2%-30.2%
Per Share
EPS$-1.72$-1.62$-1.08
Cash Flow
Operating CF--$110.0M-$33.0M
CapEx$2.5M$2.0M$1.5M

Source: XBRL data in Zymeworks Inc. (ZYME)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ZYME share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ZYME shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$420.8M
Q2 202627$385.2M
Q1 202627$396.1M
Q4 202525$405.3M
Q3 202527$306.5M
Q2 202525$223.5M
Q1 202524$139.5M
Q4 202419$95.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 201 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ZYME filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
8-KNov 16, 2026Analysis-
4Nov 16, 2026--
8-KNov 9, 2026Analysis-
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
8-KOct 23, 2026Analysis-
4Oct 9, 2026--
8-KSep 23, 2026Analysis-
8-KAug 25, 2026Analysis-
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
4Jul 6, 2026--
8-KJun 29, 2026Analysis-
4May 15, 2026-
8-KMay 14, 2026Analysis
8-KMay 7, 2026Analysis
10-QMay 7, 2026Analysis
SC 13GApr 15, 2026-
4Apr 10, 2026--
4Apr 10, 2026--
4Apr 7, 2026--
8-KApr 1, 2026--
8-KMar 2, 2026Analysis-
8-KMar 2, 2026Analysis-

Related Health Care companies

All Health Care →

ZYME SEC filings: frequently asked questions

Are ZYME insiders buying or selling?

In the last 90 days, Zymeworks Inc. (ZYME) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $1.8 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ZYME stock?

As of September 30, 2026, the largest Zymeworks Inc. (ZYME) holders among the 13F filers tracked by SignalX were BlackRock ($111.6 million), Morgan Stanley ($85.7 million), Vanguard Capital Management LLC ($41.3 million), Citadel Advisors LLC ($31.6 million), State Street Corp ($29.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ZYME's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Zymeworks Inc. (ZYME) reported revenue of $106.0 million (up 38.9% from FY2024) and a net loss of $81.1 million. Diluted EPS was -$1.08. The figures come from the XBRL data in the 10-K.

What are the main risks in ZYME's latest 10-K?

In the 10-K filed March 2, 2026, Zymeworks Inc. (ZYME) flagged: Regulatory risk: BIOSECURE Act may restrict U.S. government contracts to companies using equipment/services from certain Chinese biotech firms, affecting partnerships and operations. Geopolitical risk: Early-stage clinical supplies sourced from China exposed to ongoing U.S.-China trade tensions and tariffs, risking supply chain disruptions. (AI summary of the Risk Factors section.)

What did ZYME report in its latest 8-K?

Zymeworks Inc. (ZYME) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Second 2026 Share Repurchase Program announced, signaling continued capital return to shareholders.

What are the latest ZYME SEC filings?

Zymeworks Inc. (ZYME) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 18, 2026.

What is ZYME's SEC CIK number?

Zymeworks Inc. (ZYME)'s SEC Central Index Key (CIK) is 1937653. EDGAR lists every ZYME filing under that number.

Ask anything about ZYME

The research agent reads ZYME's filings, financials, insider trades and 13F holders, then answers with sources.